Preventative medications for fleas, mites, and ticks are effective against each of these external parasites
Neuroscience Research: BPC-157 is studied in experimental models involving dopaminergic, serotonergic, and GABAergic signaling
Cerebrolysin's Position: Decades of clinical use across 40+ countries with established safety and efficacy data Meta-analyses and Cochrane systematic reviews the highest levels of clinical evidence Known limitations: complex mixture makes precise mechanism attribution difficult, not FDA-approved, requires IV/IM administration Represents validated but incrementally effective neurotrophic therapy Dihexa's Position: Exceptional mechanistic novelty HGF/c-Met potentiation at picomolar concentrations is a genuinely unique pharmacological finding if confirmed Entirely preclinical with no human data of any kind Foundational research compromised by expression of concern and retraction the core evidence base is actively questioned Theoretical safety concerns (c-Met oncogenesis) that have not been addressed experimentally Represents frontier neuroscience that has not survived the basic tests of scientific reproducibility For Researchers: Cerebrolysin offers a clinically validated tool for studying neurotrophic effects in humans, supported by the strongest available evidence
Stay on track with ongoing care Benefit from ongoing care, support, and adjustments to your plan BluefitMD helps people discover and become the best version of themselves
administration of Ang IV, Ang II and the dopamine receptor agonist fenoldopam showed a high correlation between RBF and CBF measurements, excluding the above possibility
Faster recovery not only supports physical performance but also helps reduce the risk of injuries, making it a vital component for athletes and active individuals
